Farmas USA

Para eso lo he colgado ;-))

La semana podía haber sido cojonuda y ha acabado bien jodida,así que quizá la próxima sea mejor.
Disfruta el finde colega!

SNTA

Si, si, pero me fió de los PO igual que de los políticos españoles.......

Claro, creo que todavia no he visto cumplirse un PO mas alla de un 75%. No se toman al pie de la letra por supuesto, pero tampoco me voy a quedar en el valor mas que lo minimo imprescindible.
Pero cuando tienes que aguantar a que gire no es lo mismo estar en un valor con un precio de 15 y un PO de 18 que estar a un precio de 9 con un PO de 18, vamos, que hay mucho margen para tirar pa'rriba.
saludos

FILING del Viernes

http://www.sec.gov/Archives/edgar/data/1157601/000104746913005488/a2214972z424b2.htm

Una dilucion no creo que sea puesto que creo recordar ya la hicieron en Marzo.

Pero esto que es? Una oferta de 300 millones para acciones, opciones, etc de la propia cartera de la empresa?

SNTA

http://wire.kapitall.com/investment-idea/biotech-watchlist-2013-update-exciting-ideas-have-explosive-potential/

Cambiando de tercio, esperando los datos de Vascepa, a ver si nos dan una alegría.

SNTA

Es el folleto de venta de acciones que forma parte de una oferta pública de acciones, pero yo diría que es solo algo burrocrático para asegurarse de que pueden ofrecer todas esas acciones en los próximos siete años.

http://en.wikipedia.org/wiki/Shelf_prospectus

O podría ser también que fuera a cotizar en otro mercado o alguna operación similar, pero lo veo menos probable.

En principio debería ser algo bueno. La mala noticia es que se conceden el derecho a emitir 100 millones de acciones ordinarias; los 300 millones es el valor total. Deberíamos intentar conseguir el "registration statement" completo para asegurarnos de que no incluye ninguna sorpresa.

Párrafos estelares:

Shares of our common stock sold pursuant to the registration statement of which this prospectus is a part will be authorized for quotation and trading on The NASDAQ Global Market. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The NASDAQ Global Market or any securities market or other securities exchange of the securities covered by the prospectus supplement.

Under this prospectus, we may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants, rights or purchase contracts to purchase any of such securities, either individually or in units, with a total value of up to $300,000,000, from time to time at prices and on terms to be determined by market conditions at the time of the offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable.

We are authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. On March 8, 2013, we had 69,054,951 shares of common stock outstanding and approximately 63 stockholders of record.

We are authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share. As of March 8, 2013, no shares of our preferred stock were outstanding or designated.

We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities (1) through underwriters or dealers, (2) through agents or (3) directly to one or more purchasers, or through a combination of such methods. We may distribute the securities from time to time in one or more transactions at:

•
a fixed price or prices, which may be changed from time to time;

•
market prices prevailing at the time of sale;

•
prices related to the prevailing market prices; or

•
negotiated prices.

We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a prospectus supplement with respect to that series.

We may issue warrants to purchase shares of our common stock, preferred stock and/or debt securities in one or more series together with other securities or separately, as described in the applicable prospectus supplement.

In addition to the board of directors' ability to issue shares of preferred stock, our restated certificate of incorporation and restated bylaws contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of our company unless such takeover or change in control is approved by our board of directors.

This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities we may offer pursuant to this prospectus.

En realidad creo que es la plasmación formal de la noticia del 14 de marzo, así que nada nuevo bajo el sol. Y ya podemos respirar tranquilos. :)

http://www.researchviews.com/healthcare/pharma/hematologydisorders/DealReport.aspx?sector=Hematology%20Disorders&DealID=217953